Updated:
Zogenix Inc.
UCB, a global biopharmaceutical company, has several locations. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia.
Zogenix Inc.
UCB, a global biopharmaceutical company, has several locations. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. sites include global clinical development in Raleigh, North Carolina, our policy office in Washington, D.C., and research supporting UCB’s pipeline
General information
Firm type
other
Location
Region
North America
Country
United States
City
Emeryville
Corporate office
Emeryville, CA, United States
Frequently asked questions
Does Zogenix Inc. still operate as an independent company?
No. The domain zogenix.com now redirects to UCB's corporate site, and all public pages reference UCB's global and US operations (per UCB website, 2026). Zogenix was acquired by UCB in 2022 and no longer functions as a separate entity.
Is Zogenix Inc. a family office or asset manager?
No. Zogenix Inc. was originally a biopharmaceutical company focused on rare disease treatments. It is not structured as a family office, investment firm, or institutional allocator. There is no publicly available evidence of any investment management activity.
What happened to Zogenix's investment team and portfolio?
Following its acquisition by UCB, Zogenix's operations were integrated. No independent investment team, portfolio, or deployment activity can be identified. The firm's Altss record shows an Emeryville, CA headquarters, but that location has no current operational presence.
Is there any AUM or deployment data available for Zogenix Inc.?
No. AUM and deployment figures are not published and cannot be independently verified. The firm no longer exists as a distinct entity to report such figures.
Why is Zogenix Inc. listed in Altss?
Zogenix Inc. appears in Altss as a legacy record. The firm's website redirect suggests it was acquired and dissolved. The profile documents the current inactive status for institutional allocators seeking clarity on the entity's operational reality.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: